3rd Quarter - Report

NOSSAMAN LLP for AMERISOURCEBERGEN CORPORATION (FORMERLY "AMERISOURCEBERGEN SPECIALTY GROUP")

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Repeal of LIFO (Last in, First Out)

LobbyistCovered position, as disclosed
SHELBY LYNNE HAGENAUER —
BRENT HEBERLEE —
TIMOTHY W JENKINS —
SHERRY HARPER WIDICUS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP) generally (in the context of deficit reduction); Medicare Program Part B Drug Payment Model.

LobbyistCovered position, as disclosed
SHELBY LYNNE HAGENAUER —
BRENT HEBERLEE —
TIMOTHY W JENKINS —
SHERRY HARPER WIDICUS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

Medicare Prompt Pay Discount Exclusion, legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Proposals to exclude cancer drugs from sequestration cuts. Medicare Program Part B Drug Payment Model. Pharmaceutical compounding and implementation of the Drug Quality Security Act. Opioid legislation, including H.R. 6, the SUPPORT for Patients and Communities Act and Senate measures related to prescription drug abuse

LobbyistCovered position, as disclosed
SHELBY LYNNE HAGENAUER —
BRENT HEBERLEE —
TIMOTHY W JENKINS —
PAUL S QUINN —
SHERRY HARPER WIDICUS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.